Insys Therapeutics PE Ratio 2006-2019 | INSY

Current and historical p/e ratio for Insys Therapeutics (INSY) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Insys Therapeutics PE ratio as of June 14, 2019 is 0.00.
Insys Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-06-17 0.30 0.00
2019-03-31 4.62 $-3.06 0.00
2018-12-31 3.50 $-1.68 0.00
2018-09-30 10.08 $-1.71 0.00
2018-06-30 7.24 $-3.60 0.00
2018-03-31 6.04 $-3.34 0.00
2017-12-31 9.62 $-3.15 0.00
2017-09-30 8.88 $-2.55 0.00
2017-06-30 12.65 $-0.25 0.00
2017-03-31 10.51 $-0.08 0.00
2016-12-31 9.20 $0.04 230.00
2016-09-30 11.79 $0.31 38.03
2016-06-30 12.94 $0.65 19.91
2016-03-31 15.99 $0.69 23.17
2015-12-31 28.63 $0.77 37.42
2015-09-30 28.46 $0.67 42.48
2015-06-30 35.92 $0.49 74.06
2015-03-31 29.07 $0.52 56.44
2014-12-31 21.08 $0.52 40.93
2014-09-30 19.39 $0.73 26.68
2014-06-30 15.62 $0.74 21.05
2014-03-31 20.72 $0.70 29.66
2013-12-31 12.90 $0.59 21.74
2013-09-30 11.66 $0.00 0.00
2013-06-30 4.61 $-0.32 0.00
2013-03-31 3.67 $-0.63 0.00
2012-12-31 2.58 $-0.63 0.00
2012-09-30 2.60 $-0.38 0.00
2012-06-30 3.58 $-0.84 0.00
2012-03-31 3.83 $-1.63 0.00
2011-12-31 3.00 $-2.64 0.00
2010-06-30 6.85 $-3.86 0.00
2010-03-31 7.12 $-4.67 0.00
2009-12-31 5.90 $-5.28 0.00
2009-09-30 8.74 $-5.89 0.00
2009-06-30 5.08 $-6.30 0.00
2009-03-31 1.32 $-6.30 0.00
2008-12-31 3.30 $-5.69 0.00
2008-09-30 4.48 $-4.88 0.00
2008-06-30 10.57 $-3.86 0.00
2008-03-31 11.39 $-5.08 0.00
2007-12-31 12.00 $-7.93 0.00
2007-09-30 20.13 $-12.81 0.00
2007-06-30 23.38 $-18.09 0.00
2007-03-31 34.57 $-22.56 0.00
2006-12-31 33.96 $-24.80 0.00
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.025B $0.082B
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $145.051B 28.16
Medtronic (MDT) Ireland $130.762B 18.68
Stryker (SYK) United States $72.931B 26.03
Boston Scientific (BSX) United States $56.210B 26.95
Baxter (BAX) United States $39.757B 25.06
Zimmer Biomet Holdings (ZBH) United States $24.054B 15.45
Smith & Nephew SNATS (SNN) United Kingdom $18.710B 0.00
ResMed (RMD) United States $16.933B 32.35
Canopy Growth (CGC) Canada $14.186B 0.00
Bio-Rad Laboratories (BIO) United States $8.893B 47.15
Aurora Cannabis (ACB) Canada $7.667B 75.60
Hill-Rom Holdings (HRC) United States $6.972B 21.14
Insulet (PODD) United States $6.868B 500.39
Perrigo (PRGO) Ireland $5.872B 9.93
Haemonetics (HAE) United States $5.747B 46.91
GW Pharmaceuticals (GWPH) United Kingdom $5.154B 0.00
ICU Medical (ICUI) United States $4.983B 29.73
Hutchison China MediTech (HCM) China $3.506B 0.00
Neogen (NEOG) United States $3.232B 52.55
NuVasive (NUVA) United States $3.005B 24.54
Agios Pharmaceuticals (AGIO) United States $2.821B 0.00
National Vision Holdings (EYE) United States $2.350B 50.07
Quidel (QDEL) United States $2.233B 23.18
Aphria (APHA) $1.702B 0.00
Cardiovascular Systems (CSII) United States $1.388B 797.00
Phibro Animal Health (PAHC) United States $1.174B 17.58
AtriCure (ATRC) United States $1.144B 0.00
VAREX IMAGING (VREX) United States $1.089B 23.12
Lantheus Holdings (LNTH) United States $1.027B 27.27
OrganiGram Holdings (OGI) Canada $0.969B 0.00
NanoString Technologies (NSTG) United States $0.909B 0.00
PetIQ (PETQ) United States $0.837B 20.34
Quanterix (QTRX) United States $0.834B 0.00
Omeros (OMER) United States $0.795B 0.00
MacroGenics (MGNX) United States $0.743B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.724B 20.31
TG Therapeutics (TGTX) United States $0.639B 0.00
Cerus (CERS) United States $0.629B 0.00
Surmodics (SRDX) United States $0.558B 81.06
OraSure Technologies (OSUR) United States $0.530B 24.40
LeMaitre Vascular (LMAT) United States $0.513B 24.82
Meridian Bioscience (VIVO) United States $0.497B 15.18
Evolus (EOLS) United States $0.377B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.348B 0.00
Vapotherm (VAPO) United States $0.339B 0.00
BioLife Solutions (BLFS) United States $0.333B 104.06
Utah Medical Products (UTMD) United States $0.300B 20.78
Zynex (ZYXI) United States $0.282B 29.17
Rockwell Medical (RMTI) United States $0.241B 0.00
Bovie Medical (APYX) United States $0.213B 0.00
Cytosorbents (CTSO) United States $0.195B 0.00
Chimerix (CMRX) United States $0.179B 0.00
Owens & Minor (OMI) United States $0.177B 3.75
Fonar (FONR) United States $0.135B 7.09
Female Health (VERU) United States $0.127B 0.00
Chembio Diagnostics (CEMI) United States $0.103B 0.00
BRAINSWAY LTD (BWAY) Israel $0.094B 0.00
Surface Oncology (SURF) United States $0.092B 0.00
United-Guardian (UG) United States $0.087B 19.15
Neurotrope (NTRP) United States $0.080B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.061B 0.00
ImmuCell (ICCC) United States $0.047B 0.00
Trinity Biotech (TRIB) Ireland $0.044B 15.21
GUARDION HEALTH (GHSI) United States $0.036B 0.00
Senestech (SNES) United States $0.034B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.026B 0.00
Cellectar Biosciences (CLRB) United States $0.021B 0.00
Valeritas Holdings (VLRX) United States $0.016B 0.00
Capricor Therapeutics (CAPR) United States $0.012B 0.00
Akers Biosciences Inc (AKER) United States $0.007B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.007B 0.00
NeuroMetrix (NURO) United States $0.005B 3.82